WO2021224455A1 - Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity - Google Patents
Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity Download PDFInfo
- Publication number
- WO2021224455A1 WO2021224455A1 PCT/EP2021/062135 EP2021062135W WO2021224455A1 WO 2021224455 A1 WO2021224455 A1 WO 2021224455A1 EP 2021062135 W EP2021062135 W EP 2021062135W WO 2021224455 A1 WO2021224455 A1 WO 2021224455A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- composition
- species
- weight
- strengthening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/577—Malvaceae (Mallow family)
- A61K36/5777—Theobroma, e.g. cocao or cocoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention concerns compositions used in a method for strengthening the immune system of human and animal to acquire pan-immunity.
- compositions comprising the ingredients mentioned hereafter enabled significant improvement of health condition related to strengthened and good function of immune system.
- the present invention is a method to improve the general immunologic status, which is different from an antibiotic invention, which needs test against certain pathogens.
- the composition in the present invention has a function to ameliorate immune system as revealed at two scientifically proved levels: 1. increased volunteer wheel running activity (VWRA); and 2. down-regulation of il- 8, an indirect method to measure immune-improving or immunomodulatory bio- activity (see descriptions below).
- tyrosine hydroxylase is key for dopamine production because dopamine is derived from a two-step process starting with the hydroxylation of L-tyrosine by the enzyme TH (Sato et al. (2010), Fermented soymilk increases voluntary wheel running activity and sexual behavior in male rats. Appl. Physiol. Nutr. Metab. 35: 749 754; Wagar et al. (2009), Immunomodulatory Properties of Fermented Soy and Dairy Milks Prepared with Lactic Acid Bacteria. JOURNAL OF FOOD SCIENCE, Vol. 74, Nr. 8).
- Immunomodulatory bioactivity of a variety of bioactive components can be assessed on the pro-inflammatory response of intestinal epithelial cells (IEC)following Tumor Necrosis Factor a (TNFa) treatment, by measuring the impact on IL-8 production.
- IEC intestinal epithelial cells
- TNFa Tumor Necrosis Factor a
- down-regulation of IL-8 production has been observed (Wagar et al above), finding consistent with the observations for the immunity-improving bioactivity of the composition according to the present application, i.e. down-regulation of IL-8 production in TNFa-challenged human endothelial cells (see below “Example 2: Immunomodulatory/anti-inflammatory effect”).
- the immunomodulatory effect of the composition according to the invention is shown in the immunosuppressed mouse model by increased voluntary wheel running capacity.
- the animal model used in the application is a mouse model of fatigue induced by peripheral irradiation. It has been documented that irradiation can cause generalized immunosuppression, mainly due to lymphocyte apoptosis and dysfunction of immune regulation (McFarland et al. (2012), Regulatory T Cells in g Irradiation-Induced Immune Suppression. PLoS ONE 7(6): e39092. doi: 10.1371 /journal. pone.0039092).
- composition according to the invention comprising the ingredients mentioned hereafter, provides with a method for strengthening the immune system for good immune functions and finally acquire pan-immunity.
- cytokine storm a dangerous overreaction of the immune system.
- composition according to the invention on its immunity-improving / immunomodulatory/anti-inflammatory effect via down-regulation of TNF alpha- induced expression of pro-inflammatory molecules: Interleukin 8, ICAM-1 and E- selectin, is also presented hereafter in the Experimental Part in Tables 2-4.
- the present invention concerns a composition to be used for strengthening the immunity system containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
- the extract of Paullinia species and/or the extract of Theobroma species can be atomized or not.
- the said composition contains from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract of Paullinia species and from 0.05% to 5.0% by weight of an extract of Theobroma species, based on the total weight of the four active ingredients.
- the said composition contains from 60% to 70% by weight of an extract of Allium cepa, from 7% to 12% by weight of an extract of Citrus limon, from 0.08% to 0.20% by weight of an extract of Paullinia cupana and from 0.06% to 0.18% by weight of an extract of Theobroma cacao, based on the total weight of the four active ingredients.
- the said composition contains as excipients from 1.0% to 8.0% by weight of sodium chloride and from 10% to 40% by weight of glycerine, based on the total weight of the composition This composition is to be used to acquire pan-immunity.
- the composition is to be used to prevent and to treat infectious and other diseases with immunological components, such as viral infections and/or auto-immune diseases, including eliminating cancer cells.
- immunological components such as viral infections and/or auto-immune diseases, including eliminating cancer cells.
- this composition is to be used as adjuvant potentiator in various therapies or treatments.
- This composition is to be administrated by parenteral route, non-parenteral route, oral route or local or topical routes, or in combination thereof.
- a composition comprising the ingredients mentioned hereafter was administered topically to human subjects with abnormal conditions in terms of inflammation. It was observed that, the composition significantly improved the inflammatory skin condition thanks to the anti-inflammatory function of the composition.
- the present invention proposes a method for the improvement/strengthening of the immune system; comprising the administration by oral, parenteral, topical application, or local injection, and/or as adjuvant potentiator in various therapies/treatments, or in combination, of a composition containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
- the present invention concerns a method for strengthening immunity system; comprising the administration by oral route, or parenteral route, or topical application, or injection, or a combination thereof, of a composition containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
- a composition containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
- the preferred composition contains from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to
- the composition comprises from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, from 1.0% to 8.0% by weight of Sodium chloride and from 10% to 40% by weight of glycerine, based on the total weight of the composition.
- compositions are used not only as conventional oral composition, composition for injection (local or systemic), but also as an adjuvant potentiator in therapies/treatments for strengthening the immunity system to acquire pan-immunity.
- the compositions contain from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, based on the weight of the four active ingredients.
- the compositions contain from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, based on the total weight of the four active ingredients.
- the composition comprises from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, from 1.0% to 8.0% by weight of Sodium chloride and from 10% to 40% by weight of glycerine, based on the total weight of the composition.
- extract of Allium species refers particularly to extracts and native extracts obtained from all species of the genus Allium (family Liliaceae), and especially Allium cepa.
- the term genus citrus refers particularly to the family Rutaceae, especially Citrus limon.
- extract (atomized or not) of Paullinia species refers particularly to extracts and native extracts obtained from all species of the genus Paullinia (family Sapindaceae), especially Paullinia cupana (Guarana).
- extract (atomized or not) of Theobroma species refers particularly to aqueous-alcoholic extracts and native extracts obtained from all species of the genus Theobroma (family Malvaceae), and especially Theobroma cacao.
- compositions used according to the invention are: those containing approximately 66% by weight of an extract of Allium cepa, approximately 9% by weight of an extract of Citrus limon, approximately 0.11 % by weight of an extract (atomized or not) of Paullinia cupana and approximately 0.11 % by weight of an extract (atomized or not) of Theobroma cacao, based on the total weight of the four active ingredients.
- the composition is chronically administered in a mixture containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
- the composition is administered daily during a period of several months or longer with a composition containing as active ingredients an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
- compositions obtained according to the invention doses may vary within relatively wide limits and must be set according to the person being treated and the condition concerned.
- Pharmaceutical compositions normally contain from 0.4 to 1000 mg, preferably from 2 to 400 mg, of active ingredients as defined above, in the form of dry extract or liquid solution.
- the composition can be orally administered in human, twice daily, with 5 ml each intake.
- the present invention also concerns a composition containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species for use in strengthening the immunity system in order to acquire pan-immunity, by oral, parenteral, other above-mentioned routes, and/or as adjuvant potentiator in various therapies/treatments, or in combination thereof.
- the composition for use in strengthening the immunity system in order to acquire pan-immunity contains an extract of Allium species, an extract of Citrus species and an extract (atomized or not) of Paullinia species and an extract (atomized or not) of Theobroma species.
- the composition for use in strengthening the immunity system in order to acquire pan-immunity contains from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, based on the total weight of the four active ingredients.
- mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- Example 4 The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition: - an extract of Allium cepa (containing quercetin): 45.50 %
- Example 6 The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- Example 8 The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- excipients used in the above examples are from 1.0% to 8.0% by weight of sodium chloride and from 10% to 40% by weigh of glycerine, based on the total weight of the composition.
- mice have surprisingly shown a strengthening of their immunity system significantly demonstrated according to a mode of evidence known in the art, as explained above, measured by their increased wheel running capacity in comparison with the level of their immunity system before intake of the composition.
- composition according to the present invention is capable of positively influencing and strengthening the immunity system.
- VWRA Running Activity
- composition group (“Drug”) was 17% greater than Placebo group. “The composition” group mice returned to daily running distance baseline after 7 days; placebo mice returned to baseline running distance 12 days after irradiation.
- Example 2 Immunity-improving/Immunomodulatory/anti-inflammatory effect The study outcome summary is presented below in Tables 2-4.
- composition within the ranges in the examples 1 to 10 containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species, was used to perform the study on its immunity-improving/immunomodulatory/anti-inflammatory effect via down- regulation of TNF alpha-induced expression of pro-inflammatory molecules: Interleukin-8, ICAM-1 and E-selectin, as summarized in Table 2-4.
- a composition according to the invention enabled modulation of the over-reaction of immune response through anti-inflammation. Consequently, the composition improved health condition as a result of good functioning of the strengthened immune system.
- a composition according to the invention provides a method for strengthening the immune system for good immune functions and finally acquire pan-immunity.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022567246A JP2023529062A (en) | 2020-05-07 | 2021-05-07 | Compositions used to strengthen the immune system to achieve pan-immunity in humans and animals |
| AU2021267004A AU2021267004A1 (en) | 2020-05-07 | 2021-05-07 | Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity |
| BR112022021695A BR112022021695A2 (en) | 2020-05-07 | 2021-05-07 | COMPOSITION TO BE USED TO STRENGTHEN THE IMMUNE SYSTEM IN HUMANS AND ANIMALS TO ACQUIRE PAN-IMMUNITY |
| CN202180033443.9A CN115666525A (en) | 2020-05-07 | 2021-05-07 | Compositions for enhancing the immune system of humans and animals to obtain various immunities |
| EP21723282.6A EP4146169A1 (en) | 2020-05-07 | 2021-05-07 | Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity |
| US17/922,884 US20230270812A1 (en) | 2020-05-07 | 2021-05-07 | Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity |
| KR1020227041721A KR20230007451A (en) | 2020-05-07 | 2021-05-07 | Compositions used for enhancing the immune system of humans and animals to obtain pan-immunity |
| MX2022013868A MX2022013868A (en) | 2020-05-07 | 2021-05-07 | Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity. |
| CA3177105A CA3177105A1 (en) | 2020-05-07 | 2021-05-07 | Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2004533A FR3109881B1 (en) | 2020-05-07 | 2020-05-07 | PROCESS FOR IMPROVING THE IMMUN SYSTEM TO ACQUIRE PAN-IMMUNITY |
| FRFR2004533 | 2020-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021224455A1 true WO2021224455A1 (en) | 2021-11-11 |
Family
ID=72644307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2021/062135 Ceased WO2021224455A1 (en) | 2020-05-07 | 2021-05-07 | Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230270812A1 (en) |
| EP (1) | EP4146169A1 (en) |
| JP (1) | JP2023529062A (en) |
| KR (1) | KR20230007451A (en) |
| CN (1) | CN115666525A (en) |
| AU (1) | AU2021267004A1 (en) |
| BR (1) | BR112022021695A2 (en) |
| CA (1) | CA3177105A1 (en) |
| FR (1) | FR3109881B1 (en) |
| MX (1) | MX2022013868A (en) |
| WO (1) | WO2021224455A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11819530B1 (en) | 2023-05-17 | 2023-11-21 | Legacy Healthcare (Switzerland) Sa | Long term treatment of hair loss |
| WO2024236145A1 (en) * | 2023-05-17 | 2024-11-21 | Legacy Healthcare (Switzerland) Sa | Long term treatment of hair loss |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2912310A1 (en) * | 2007-02-13 | 2008-08-15 | Kasan Sarl | Cosmetic or pharmaceutical compositions comprise allium and citrus extracts and a combination of paullinia and theobroma extracts or a combination of a salix extract and zinc sulfate |
| WO2012140013A2 (en) * | 2011-04-11 | 2012-10-18 | Legacy Healthcare Holding Ltd | New use of compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling. |
| US20130323334A1 (en) * | 2011-02-23 | 2013-12-05 | Legacy Healthcare Ltd. | Use Of Compositions For Preventing Chemotherapy And Radiotherapy Induced Alopecia (CRIA), Reducing CRIA Impact And Improving The Appearance Of Hair Re-Growth After CRIA |
| WO2017186954A1 (en) * | 2016-04-28 | 2017-11-02 | Legacy Healthcare Ltd | Method for the improvement of speed and endurance capacity |
| US20190314441A1 (en) * | 2013-11-08 | 2019-10-17 | Legacy Healthcare Ltd. | Method For The Management Of Cancer And Cancer Treatment-Related Comorbidities |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013020719A2 (en) * | 2011-08-09 | 2013-02-14 | Legacy Healthcare Holding Ltd | New use of compositions to delay the onset of the catagen phase of the hair |
| EP2862598A1 (en) * | 2013-10-16 | 2015-04-22 | Legacy Healthcare Holding Ltd. | Use of a composition for the pigmentation of hair and hairs |
-
2020
- 2020-05-07 FR FR2004533A patent/FR3109881B1/en active Active
-
2021
- 2021-05-07 KR KR1020227041721A patent/KR20230007451A/en active Pending
- 2021-05-07 MX MX2022013868A patent/MX2022013868A/en unknown
- 2021-05-07 AU AU2021267004A patent/AU2021267004A1/en not_active Abandoned
- 2021-05-07 WO PCT/EP2021/062135 patent/WO2021224455A1/en not_active Ceased
- 2021-05-07 CA CA3177105A patent/CA3177105A1/en active Pending
- 2021-05-07 US US17/922,884 patent/US20230270812A1/en not_active Abandoned
- 2021-05-07 EP EP21723282.6A patent/EP4146169A1/en not_active Withdrawn
- 2021-05-07 BR BR112022021695A patent/BR112022021695A2/en not_active Application Discontinuation
- 2021-05-07 JP JP2022567246A patent/JP2023529062A/en active Pending
- 2021-05-07 CN CN202180033443.9A patent/CN115666525A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2912310A1 (en) * | 2007-02-13 | 2008-08-15 | Kasan Sarl | Cosmetic or pharmaceutical compositions comprise allium and citrus extracts and a combination of paullinia and theobroma extracts or a combination of a salix extract and zinc sulfate |
| US20130323334A1 (en) * | 2011-02-23 | 2013-12-05 | Legacy Healthcare Ltd. | Use Of Compositions For Preventing Chemotherapy And Radiotherapy Induced Alopecia (CRIA), Reducing CRIA Impact And Improving The Appearance Of Hair Re-Growth After CRIA |
| WO2012140013A2 (en) * | 2011-04-11 | 2012-10-18 | Legacy Healthcare Holding Ltd | New use of compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling. |
| US20190314441A1 (en) * | 2013-11-08 | 2019-10-17 | Legacy Healthcare Ltd. | Method For The Management Of Cancer And Cancer Treatment-Related Comorbidities |
| WO2017186954A1 (en) * | 2016-04-28 | 2017-11-02 | Legacy Healthcare Ltd | Method for the improvement of speed and endurance capacity |
Non-Patent Citations (7)
| Title |
|---|
| KANG DANBEE ET AL: "Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT)", SUPPORTIVE CARE IN CANCER, SPRINGER VERLAG, BERLIN, DE, vol. 28, no. 4, 23 July 2019 (2019-07-23), pages 1829 - 1837, XP037030508, ISSN: 0941-4355, [retrieved on 20190723], DOI: 10.1007/S00520-019-04982-Z * |
| MATT ET AL.: "Where Is Dopamine and how do Immune Cells See it?:Dopamine-Mediated Immune Cell Function in Health and Disease", JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 11 May 2019 (2019-05-11) |
| MCFARLAND ET AL.: "Regulatory T Cells in y Irradiation-Induced Immune Suppression", PLOS ONE, vol. 7, no. 6, 2012, pages e39092 |
| SATO ET AL.: "Fermented soymilk increases voluntary wheel running activity and sexual behavior in male rats", APPL. PHYSIOL. NUTR. METAB., vol. 35, 2010, pages 749 - 754 |
| See also references of EP4146169A1 |
| WAGAR ET AL.: "Immunomodulatory Properties of Fermented Soy and Dairy Milks Prepared with Lactic Acid Bacteria", JOURNAL OF FOOD SCIENCE, vol. 74, no. 8, 2009, XP055318149, DOI: 10.1111/j.1750-3841.2009.01308.x |
| ZHANG ET AL.: "Brain region-dependent gene networks associated with selective breeding for increased voluntary wheel-running behavior", PLOS ONE, 2 August 2018 (2018-08-02), Retrieved from the Internet <URL:https:lldoi.orgl]O.137]ljournalpone.0201773> |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11819530B1 (en) | 2023-05-17 | 2023-11-21 | Legacy Healthcare (Switzerland) Sa | Long term treatment of hair loss |
| WO2024236145A1 (en) * | 2023-05-17 | 2024-11-21 | Legacy Healthcare (Switzerland) Sa | Long term treatment of hair loss |
Also Published As
| Publication number | Publication date |
|---|---|
| FR3109881A1 (en) | 2021-11-12 |
| MX2022013868A (en) | 2023-02-09 |
| US20230270812A1 (en) | 2023-08-31 |
| BR112022021695A2 (en) | 2022-12-20 |
| FR3109881B1 (en) | 2022-10-21 |
| CN115666525A (en) | 2023-01-31 |
| AU2021267004A1 (en) | 2022-12-15 |
| KR20230007451A (en) | 2023-01-12 |
| EP4146169A1 (en) | 2023-03-15 |
| CA3177105A1 (en) | 2021-11-11 |
| JP2023529062A (en) | 2023-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116490198A (en) | Aloe-based compositions comprising polysaccharides and polyphenols for regulating immune homeostasis | |
| Bao et al. | Evaluation of pharmacodynamic activities of EPs® 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis | |
| US20230270812A1 (en) | Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity | |
| CN108420826B (en) | Use of Lycium barbarum polysaccharide in preparing medicine for treating or relieving depression and pharmaceutical composition containing the same | |
| Omer et al. | A review on the antiviral activity of functional foods against COVID-19 and viral respiratory tract infections | |
| US20110160136A1 (en) | Polyphenols for the treatment of cartilage disorders | |
| KR101740028B1 (en) | Composition for preventing, improving, or treating arthritis comprising Achyranthis Japonicae Radix and Scutellariae Radix or Achyranthis Japonicae Radix, Scutellariae Radix and Acanthopanacis Cortex | |
| Ahmed et al. | Navel orange peel ethanolic extract and naringin ameliorate CFA-induced arthritis in Wistar rats through their modulatory effects on Th1/Th2/Th17 cytokines and oxidative stress | |
| CN103656048B (en) | Medicine being used for the treatment of mammitis of cow and preparation method thereof | |
| US8609155B2 (en) | Dietary supplement stimulating the male sexual function | |
| CN111067971A (en) | Traditional Chinese medicine composition for treating paronychia and using method thereof | |
| Bilir et al. | Evaluation of the effect of Anatolian propolis on Covid-19 in healthcare professionals: Effect of Anatolian propolis on Covid-19 | |
| KR20070100560A (en) | Functional drink for strengthening immunity and manufacturing method thereof | |
| Al-Hasnawi et al. | Effect of Aloe vera extract on some parameter complete blood count and liver functions induced by azathioprine in changes male rats | |
| CN103142943B (en) | Traditional Chinese medicine composite with immune function and used for treating mastitis of cows | |
| KR102087338B1 (en) | Functional food for preventing or improving osteoarthritis containing an extract of Angelica gigas Nakai | |
| RU2248212C2 (en) | Preparation for treatment of bacterial vaginitis, method for its preparing and method for treatment of bacterial vaginitis | |
| US20160367719A1 (en) | Fractions of extracts of helichrysum having mucohadhesive properties | |
| Yang et al. | Aucubin alleviates methotrexate‐induced enteritis in rats by inducing autophagy | |
| US20200246411A1 (en) | Anti-diarrhoeal herbal compositions | |
| Surai et al. | Silymarin and inflammation: From understanding molecular mechanisms to practical applications | |
| CN105561302A (en) | Psoriasis treating medicine containing lysozyme | |
| US6248372B1 (en) | Bioactive rice flour extract useful for treatment of haemophilus influenzae infections | |
| Nongrum et al. | Possible role of Immunonutrients in combating Covid-19 outbreak | |
| FR3145272A1 (en) | Anti-inflammatory composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21723282 Country of ref document: EP Kind code of ref document: A1 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| ENP | Entry into the national phase |
Ref document number: 3177105 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2022567246 Country of ref document: JP Kind code of ref document: A |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022021695 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 20227041721 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202217070275 Country of ref document: IN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2021723282 Country of ref document: EP Effective date: 20221207 |
|
| ENP | Entry into the national phase |
Ref document number: 2021267004 Country of ref document: AU Date of ref document: 20210507 Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 112022021695 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221026 |



